Median Diagnostics Inc. engages in the manufacture and supply of in vitro diagnostic products for animal diseases and raw materials for human disease diagnosis. It operates through the following business divisions: Immunodiagnosis, Microbiological diagnosis, Molecular Diagnostics, Clinical chemistry tests, Blood test, and Urine test. The Immunodiagnosis division uses fluorescent labels, enzymes, and other chemical indicators to detect and quantify the analyte. The Microbiological diagnosis division includes identification of bacterial pathogens, virus culture and isolation, and antibiotic susceptibility testing. The Molecular Diagnostics division offers tests for unique nucleic acid sequences. The Clinical Chemistry tests division examines the health of companion animals. The Blood test division deals with the analysis of infections, inflammation, immunodeficiency, anemia, leukemia and other hematological disorders in animals. The Urine test division handles conditions including liver disease, kidney disease and dysfunction, diabetes, infections and other potential diseases. The company was founded on October 18, 1999 and is headquartered in Chuncheon-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company